Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock - Currency: USD

37.46  +0.6 (+1.63%)

After market: 37.46 0 (0%)

Fundamental Rating

4

CRNX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While CRNX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRNX had negative earnings in the past year.
In the past year CRNX has reported a negative cash flow from operations.
CRNX had negative earnings in each of the past 5 years.
In the past 5 years CRNX always reported negative operating cash flow.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

CRNX has a better Return On Assets (-29.65%) than 68.74% of its industry peers.
The Return On Equity of CRNX (-33.36%) is better than 76.55% of its industry peers.
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRNX has more shares outstanding
Compared to 5 years ago, CRNX has more shares outstanding
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 18.64 indicates that CRNX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 18.64, CRNX belongs to the top of the industry, outperforming 92.72% of the companies in the same industry.
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.64
ROIC/WACCN/A
WACC9.44%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

A Current Ratio of 16.38 indicates that CRNX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.38, CRNX belongs to the best of the industry, outperforming 89.88% of the companies in the same industry.
CRNX has a Quick Ratio of 16.38. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 16.38, CRNX belongs to the top of the industry, outperforming 89.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.38
Quick Ratio 16.38
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.47%.
The Revenue for CRNX has decreased by -78.03% in the past year. This is quite bad
Measured over the past years, CRNX shows a quite strong growth in Revenue. The Revenue has been growing by 10.55% on average per year.
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%

3.2 Future

CRNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.22% yearly.
CRNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 160.91% yearly.
EPS Next Y-1.94%
EPS Next 2Y-3.25%
EPS Next 3Y-5.79%
EPS Next 5Y13.22%
Revenue Next Year-61.64%
Revenue Next 2Y8.35%
Revenue Next 3Y111.42%
Revenue Next 5Y160.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as CRNX's earnings are expected to decrease with -5.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.25%
EPS Next 3Y-5.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (2/21/2025, 8:10:56 PM)

After market: 37.46 0 (0%)

37.46

+0.6 (+1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners108.5%
Inst Owner Change-92.78%
Ins Owners1.91%
Ins Owner Change0.03%
Market Cap3.47B
Analysts86
Price Target76.94 (105.39%)
Short Float %8.27%
Short Ratio8.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.32%
Min EPS beat(2)-7.29%
Max EPS beat(2)-3.35%
EPS beat(4)0
Avg EPS beat(4)-6.4%
Min EPS beat(4)-12.64%
Max EPS beat(4)-2.31%
EPS beat(8)0
Avg EPS beat(8)-6.4%
EPS beat(12)1
Avg EPS beat(12)-7.31%
EPS beat(16)2
Avg EPS beat(16)-7.17%
Revenue beat(2)0
Avg Revenue beat(2)-61.65%
Min Revenue beat(2)-100%
Max Revenue beat(2)-23.3%
Revenue beat(4)1
Avg Revenue beat(4)-19.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)145.52%
Revenue beat(8)5
Avg Revenue beat(8)126.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.93%
PT rev (3m)0.88%
EPS NQ rev (1m)0.08%
EPS NQ rev (3m)-0.26%
EPS NY rev (1m)0.33%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)-3.51%
Revenue NQ rev (3m)-1.32%
Revenue NY rev (1m)2.19%
Revenue NY rev (3m)-17.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3343.64
P/FCF N/A
P/OCF N/A
P/B 4.17
P/tB 4.17
EV/EBITDA N/A
EPS(TTM)-3.73
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0.01
BVpS8.98
TBVpS8.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.43%
Cap/Sales 361.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.38
Quick Ratio 16.38
Altman-Z 18.64
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)214.72%
Cap/Depr(5y)143.85%
Cap/Sales(3y)64.19%
Cap/Sales(5y)101.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
EPS Next Y-1.94%
EPS Next 2Y-3.25%
EPS Next 3Y-5.79%
EPS Next 5Y13.22%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%
Revenue Next Year-61.64%
Revenue Next 2Y8.35%
Revenue Next 3Y111.42%
Revenue Next 5Y160.91%
EBIT growth 1Y-47.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.8%
EBIT Next 3Y-26.4%
EBIT Next 5YN/A
FCF growth 1Y-95.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.18%
OCF growth 3YN/A
OCF growth 5YN/A